SCHEMBL30765758

SCHEMBL30765758

CCCCOC(=O)Cn1c(SC)nnc(N[C@H](C)c2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.40
GAA P10253 1/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 4/20 0.36
POLB P06746 1/20 0.36
LMNA P02545 2/20 0.35
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
TSHR P16473 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MAPK1 P28482 1/20 0.34
SIRT3 Q9NTG7 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
ALOX15 P16050 1/20 0.33
NR1I2 O75469 1/20 0.33
AHR P35869 1/20 0.33
MCHR1 Q99705 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765675 0.88 L3MBTL1 (0.40) L3MBTL1GAAMEN1KMT2AMAPT
SCHEMBL30766030 0.88 L3MBTL1 (0.40) L3MBTL1GAAMEN1KMT2AMAPT
SCHEMBL30765893 0.87 ALDH1A1 (0.33) MEN1KMT2AMAPTPOLBLMNA
SCHEMBL30765685 0.85 GAA (0.41) L3MBTL1GAAMEN1KMT2AMAPT
SCHEMBL30765802 0.84 GAA (0.40) L3MBTL1GAAMEN1KMT2AMAPT
SCHEMBL30765804 0.83 L3MBTL1 (0.40) L3MBTL1GAAMEN1KMT2AMAPT
SCHEMBL30765922 0.80 LMNA (0.39) L3MBTL1GAAMEN1KMT2AMAPT
SCHEMBL30765920 0.80 L3MBTL1 (0.41) L3MBTL1GAAMEN1KMT2AMAPT
SCHEMBL30765510 0.80 L3MBTL1 (0.41) L3MBTL1GAAMEN1KMT2AMAPT
SCHEMBL30765588 0.79 MEN1 (0.42) L3MBTL1GAAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed